A Phase I Study of the Treatment of Recurrent Primary or Secondary CNS Lymphoma With ALIMTA (Pemetrexed), a Novel Anti-Folate.
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2015
At a glance
- Drugs Pemetrexed (Primary)
- Indications CNS cancer; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 22 Sep 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 22 Oct 2013 Planned number of patients changed from 49 to 30 as reported by ClinicalTrials.gov.
- 22 Oct 2013 Planned end date changed from 1 Jan 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov.